CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Triple negative breast cancer (TNBC) represents approximately 15% of all breast cancers (BC) wo ...
Phase 1, Phase 2
Madrid, Spain and 23 other locations
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of trilaciclib versus placebo a...
Phase 3
Madrid, Majadahonda, Spain and 70 other locations
This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. -...
Phase 1, Phase 2
Madrid, Other, Spain and 49 other locations
with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not...
Phase 3
Madrid, Spain and 75 other locations
This study will assess the efficacy and safety of Niraparib in participants with either tumor mutation in the BRCA gene (tBRCAmut) HER2- breast...
Phase 3
Madrid, Spain and 226 other locations
in patients with unresectable locally advanced or metastatic triple negative breast cancer (TNBC), refractory to ...
Phase 2
Madrid, Spain and 9 other locations
the efficacy and safety of atezolizumab plus chemotherapy compared with placebo plus chemotherapy in patients with inoperable recurrent triple...
Phase 3
Madrid, Spain and 137 other locations
previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do no...
Phase 3
Madrid, Spain and 506 other locations
for patients with previously untreated, locally advanced, unresectable or metastatic (Stage IV) programmed death-ligand 1 (PD-L1)-positive triple...
Phase 2
Madrid, Spain and 70 other locations
with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors ...
Phase 3
Madrid, Spain and 508 other locations
Clinical trials
Research sites
Resources
Legal